On June 23, 2023 Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, reported the six abstracts accepted for oral and poster presentation at the upcoming Society for Nuclear Medicine & Molecular Imaging (SNMMI) 2023 Annual Meeting, which will be held in Chicago, June 24-27, 2023 (Press release, Actinium Pharmaceuticals, JUN 23, 2023, View Source [SID1234632870]). These abstracts exhibit the breadth of Actinium’s technological and clinical endeavors over the past year that are now culminating in targeted radiotherapies that meaningfully improve the outcomes of cancer patients.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the SNMMI oral presentations:

Presentation Title: Machine learning applications to optimize dosimetric imaging of I131-apamistamab for bone marrow conditioning in relapsed/refractory acute myeloid leukemia (R/R AML)
Session: New Developments in Radiopharmaceutical Therapy
Date and Time: June 25, 5:00pm – 6:15pm CT

Presentation Title: Individualized dosing for high-dose targeted radiation of hematopoietic cells with Iomab-B (I131-apamistamab) prior to HCT in relapsed/refractory acute myeloid leukemia (R/R AML): Safety and efficacy results from the pivotal phase 3 SIERRA trial
Session: Hematologic Malignancies
Date and Time: June 26, 12:45 PM – 2:00 PM CT

Presentation Title: Administration and radiation safety of high-dose Iomab-B (I131-apamistamab) demonstrated in multiple clinical settings: Experience from the large multicenter phase 3 SIERRA trial for targeted conditioning of patients with relapsed/refractory AML
Session: Hematologic Malignancies
Date and Time: June 26, 12:45 PM – 2:00 PM CT

Details of the SNMMI poster presentations:

All posters will be accessible for viewing for the entirety of the conference. The general session is Science Pavilion – Meet the Authors Session: June 26, 5:15pm – 6:15pm CT

Abstract Title: Organ-specific dosimetry to estimate potential toxicity thresholds of Actimab-A (lintuzumab-Ac225) used in combination with venetoclax in relapsed/refractory AML
Track: Molecular Targeting Probes
Date and Time: June 25, 6:30 – 8:30 pm CT

Abstract Title: Relative biological effectiveness of antibody radioconjugates (ARCs): In vitro dosimetric evaluation to streamline pre-clinical decision-making
Track: Oncology, Basic and Translational
Date and Time: June 27, 12:30 – 2:00 pm CT

Abstract Title: Streamlining personalized dosimetry for I131-apamistamab using a Co-57 sheet source to circumvent the need for radionuclide-specific attenuation correction
Track: Molecular Targeting Probes-Radioactive & Nonradioactive
Date and Time: June 27, 12:30 – 2:00 pm CT